Attenuated variant of the rift valley fever virus, composition comprising same, and uses thereof
AssigneeConsejo Superior De Investigaciones Cientificas (Csic)
InventorsAlejandro Brun Torres, María Belén Borrego Rivero, Sandra Moreno Fernández
Life of this patent
Estimating the term…
Abstract
The invention relates to an attenuated variant of the Rift Valley Fever Virus (RVFV) with mutations in the amino acid sequence coded by segments L, M and S of RVFV RNA; a pharmaceutical or veterinary composition comprising same; an attenuated RVFV variant for use in the prevention of Rift Valley Fever, and a vaccine against Rift Valley Fever comprising the attenuated RVFV variant. Attenuated RVFV variants with the mutations Gly924Ser and Ala303Thr in protein L, and the Pro82Leu substitution in protein NSs, are also included.
Claims12
An attenuated variant of the Rift Valley Fever virus (RVFV), wherein the RNA-dependent RNA polymerase (RdRp) protein encoded by the L segment of the RNA of said variant comprises the substitutions:
- the amino acid at position 924 is serine (L[Gly924Ser]);
- the amino acid at position 1303 is threonine (L[Ala1303Thr]);
- wherein the sequence SEQ ID NO:
- 47 of wild strain 56/74 of the RVF virus or the sequence SEQ ID NO:
- 54 of the wild type ZH548 strain of the RVF virus, are the reference sequences for the numbering of the amino acids of said protein;
- and the non-structural (NSs) protein encoded by the S segment of the RNA of said variant comprises the substitution:
- the amino acid at position 82 is leucine (NSs[Pro82Leu]);
- wherein the sequence SEQ ID NO:
- 49 of wild strain 56/74 of the RVF virus or the sequence SEQ ID NO:
- 56 of the wild type ZH548 strain of the RVF virus, are the reference sequences for the numbering of the amino acids of said protein.
Dependencies are inferred from the claim text.